Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 12.76
+0.02 (0.16%)
Feb 4, 2026, 12:05 PM CST
SHE:301211 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 422.66 | 437.76 | 651.42 | 511.65 | 539.75 | 592.36 |
Other Revenue | 8.11 | 8.11 | 11.61 | 3.26 | 0.87 | 0.57 |
| 430.77 | 445.86 | 663.03 | 514.91 | 540.62 | 592.92 | |
Revenue Growth (YoY) | -5.24% | -32.75% | 28.77% | -4.76% | -8.82% | -10.17% |
Cost of Revenue | 338.18 | 317.79 | 397.55 | 369.78 | 358.33 | 298.54 |
Gross Profit | 92.59 | 128.07 | 265.47 | 145.13 | 182.3 | 294.38 |
Selling, General & Admin | 65.19 | 61.71 | 62.09 | 47.9 | 38.54 | 67.77 |
Research & Development | 26.87 | 32.94 | 52.77 | 19.84 | 18.28 | 22.98 |
Other Operating Expenses | 3.84 | 3.77 | 5.92 | 3.96 | 5.89 | 3.15 |
Operating Expenses | 94.85 | 98.44 | 120.07 | 69.78 | 64.23 | 94.33 |
Operating Income | -2.26 | 29.64 | 145.4 | 75.35 | 118.06 | 200.05 |
Interest Expense | -0.26 | -0.31 | -0.31 | -0.34 | - | -2.28 |
Interest & Investment Income | 20.7 | 51.33 | 47.84 | 61.02 | 13.1 | 9.05 |
Currency Exchange Gain (Loss) | 3.34 | 3.34 | 3.36 | 4.78 | -3.62 | -10.44 |
Other Non Operating Income (Expenses) | -1.74 | -0.27 | -0.39 | -0.44 | 0.13 | -0.18 |
EBT Excluding Unusual Items | 19.77 | 83.72 | 195.9 | 140.36 | 127.68 | 196.2 |
Gain (Loss) on Sale of Investments | 21.67 | 14.58 | 4.02 | - | - | - |
Gain (Loss) on Sale of Assets | 0.01 | - | 0.18 | 0.04 | -0.07 | -0.03 |
Asset Writedown | -2.14 | -0.11 | -2.58 | -0.66 | -0 | -0.35 |
Other Unusual Items | 1.65 | 2.23 | 5.3 | 7.69 | 11.58 | 2.81 |
Pretax Income | 40.96 | 100.42 | 202.82 | 147.44 | 139.18 | 198.63 |
Income Tax Expense | 3.14 | 8.87 | 26.7 | 21.65 | 17.54 | 30.56 |
Earnings From Continuing Operations | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 |
Net Income | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 |
Net Income to Common | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 |
Net Income Growth | -64.41% | -48.02% | 40.01% | 3.41% | -27.62% | 67.59% |
Shares Outstanding (Basic) | 418 | 415 | 419 | 415 | 311 | 314 |
Shares Outstanding (Diluted) | 418 | 415 | 419 | 415 | 311 | 314 |
Shares Change (YoY) | 0.56% | -0.91% | 0.97% | 33.19% | -1.01% | 0.90% |
EPS (Basic) | 0.09 | 0.22 | 0.42 | 0.30 | 0.39 | 0.53 |
EPS (Diluted) | 0.09 | 0.22 | 0.42 | 0.30 | 0.39 | 0.53 |
EPS Growth | -64.61% | -47.54% | 38.66% | -22.36% | -26.88% | 66.10% |
Free Cash Flow | -21.61 | -68.36 | -49.47 | 174.84 | 102.92 | 108.28 |
Free Cash Flow Per Share | -0.05 | -0.17 | -0.12 | 0.42 | 0.33 | 0.34 |
Dividend Per Share | 0.172 | 0.172 | 0.331 | 0.230 | 0.172 | - |
Dividend Growth | -47.91% | -47.91% | 43.98% | 33.35% | - | - |
Gross Margin | 21.49% | 28.73% | 40.04% | 28.18% | 33.72% | 49.65% |
Operating Margin | -0.53% | 6.65% | 21.93% | 14.63% | 21.84% | 33.74% |
Profit Margin | 8.78% | 20.53% | 26.56% | 24.43% | 22.50% | 28.35% |
Free Cash Flow Margin | -5.02% | -15.33% | -7.46% | 33.96% | 19.04% | 18.26% |
EBITDA | 24.64 | 53.68 | 165.63 | 95.73 | 137.43 | 218.24 |
EBITDA Margin | 5.72% | 12.04% | 24.98% | 18.59% | 25.42% | 36.81% |
D&A For EBITDA | 26.91 | 24.05 | 20.23 | 20.38 | 19.37 | 18.19 |
EBIT | -2.26 | 29.64 | 145.4 | 75.35 | 118.06 | 200.05 |
EBIT Margin | -0.53% | 6.65% | 21.93% | 14.63% | 21.84% | 33.74% |
Effective Tax Rate | 7.66% | 8.83% | 13.16% | 14.68% | 12.60% | 15.38% |
Revenue as Reported | 430.77 | 445.86 | 663.03 | 514.91 | 540.62 | 592.92 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.